Metformin on Risk of Post-Covid Disease 2019 Condition Among Overweight Individuals or Obese: A Population-based Retrospective, 2025, Chaichana et al

Mij

Senior Member (Voting Rights)

Abstract​

Background
A subgroup analysis of the COVID-OUT trial's long-term outcome found that starting metformin within 3 days of coronavirus disease 2019 (COVID-19) diagnosis reduced post–COVID-19 condition (PCC) incidence by 63% in overweight or obese individuals. However, its generalizability remains uncertain.

Objectives
To evaluate the effectiveness of metformin in preventing PCC in adults with overweight or obesity who had a recent COVID-19 infection.

Design
A retrospective cohort study using a sequential target trial emulation framework.

Data Sources
The United Kingdom primary care data from the Clinical Practice Research Datalink Aurum database from March 2020 to July 2023.

Participants
Adults with overweight or obesity (body mass index ≥ 25 kg/m²) and a record of severe acute respiratory syndrome coronavirus 2 infection were included. Exclusions included metformin use in the prior year or metformin contraindications.

Measurements
The outcome was PCC, defined by a PCC diagnostic code or at least 1 World Health Organization–listed symptoms between 90 and 365 days after diagnosis, with no prior history of the symptom within 180 days before infection. The pooled hazard ratio and risk difference for the incidence of PCC were adjust for baseline characteristics.

Results
Among 624 308 patients, 2976 initiated metformin within 90 days of COVID-19 diagnosis. The 1-year risk difference for PCC in the intention-to-treat analysis was −12.58% (hazard ratio 0.36; 95% CI, 0.32–0.41), with consistent results in subgroup analyses.
LINK
 
Back
Top Bottom